A Phase 4 interventional study of Apalutamide and Placebo in Prostatic Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 27 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 36th largest by enrollment, is one of 6 that started in 2019, is one of 2 in phase 4, and was the 43rd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Marco Oderda · Sites in Italy
Ages 18–80 · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only
By country, each count listing its studies:
apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 39 · Phase 3 16 · Phase 4 2
First in 2010; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 81 across the 70 interventional studies. Of the 29 that completed or were terminated, 16 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 70 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 36th largest by enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2019, is one of 2 in phase 4, and was the 63rd registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
9 of the studies testing apalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT06274047Phase 3M.D. Anderson Cancer CenterPROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | 2027-06-30 |
| NCT06067269Jonsson Comprehensive Cancer CenterHormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | 2026-12-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 [PCWG2]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive apalutamide 240 mg orally daily from Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study along with androgen-deprivation therapy (ADT). Each treatment cycle will consist of 28 days.
Drug: Apalutamide · Drug: Androgen-deprivation Therapy (ADT)
Participants will receive matching placebo daily along with ADT from Cycle 1 Day 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study. Participants who do not have distant metastasis will switch to treatment with apalutamide after completion of 5 cycles of placebo treatment. Participants who have prostate-specific antigen (PSA) progression prior to completion of 5 cycles of study treatment, will cross over to apalutamide at the time of PSA progression. Each treatment cycle will consist of 28 days.
Drug: Placebo · Drug: Androgen-deprivation Therapy (ADT)
Apalutamide 240 mg (4\*60 mg tablets) will be administrated orally once daily.
Also known as: JNJ-56021927, ARN-509
Matching placebo will be administered orally.
Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
Time to Prostate Specific Antigen (PSA) Progression (TTPP) Based on Prostate Cancer Working Group 2 (PCWG2) Criteria
Time to prostate specific antigen progression (TTPP) was defined as the time from randomization to the first date of documented PSA progression based on PCWG2 criteria. PCWG2 was defined as the PSA progression as 1) the date that a 25 percent (%) or greater increase and an absolute increase of 2 nanograms per milliliter (ng/mL) or more from the Nadir was documented, which was confirmed by a second value obtained 3 or more weeks later. 2) Where no decline from baseline was documented as a 25% increase from the baseline value along with an increase in absolute value of 2 ng/mL or more after 12 week of treatment. Kaplan-Meier method was used for the analysis.
Time frame: From randomization until first documented PSA progression (up to 3 years 3 months)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Time frame: Up to 6 years 4 months
Number of Participants With Grade 3 or Higher Abnormalities in Laboratory Values
Time frame: Up to 6 years 4 months
Percentage of Participants Who Achieved Prostate Specific Antigen (PSA) Response (>=50% PSA Reduction)
Time frame: Up to 6 years 4 months
Plasma Concentration of Apalutamide and Its Metabolite (N-desmethyl Apalutamide)
Time frame: Presdose: Day 1 of Cycles 1, 2, 3, and 6; 2 hours postdose: Day 1 of Cycles 1 and 3
| Milestone | Placebo Plus Androgen-deprivation Therapy (ADT) | Apalutamide 240 mg Plus ADT |
|---|---|---|
| Started | 25 | 50 |
| Crossed-over to apalutamide | 22 | 0 |
| Completed | 0 | 0 |
| Not completed | 25 | 50 |
| Withdrew: Withdrawal by subject | 2 | 6 |
| Withdrew: Other-ongoing | 20 | 40 |
| Withdrew: Death | 1 | 4 |
| Withdrew: Lost to follow-up | 2 | 0 |
Time to prostate specific antigen progression (TTPP) was defined as the time from randomization to the first date of documented PSA progression based on PCWG2 criteria. PCWG2 was defined as the PSA progression as 1) the date that a 25 percent (%) or greater increase and an absolute increase of 2 nanograms per milliliter (ng/mL) or more from the Nadir was documented, which was confirmed by a second value obtained 3 or more weeks later. 2) Where no decline from baseline was documented as a 25% increase from the baseline value along with an increase in absolute value of 2 ng/mL or more after 12 week of treatment. Kaplan-Meier method was used for the analysis.
| Months | Placebo Plus Androgen-deprivation Therapy (ADT) | Apalutamide 240 mg Plus ADT |
|---|---|---|
| Time to Prostate Specific Antigen (PSA) Progression (TTPP) Based on Prostate Cancer Working Group 2 (PCWG2) Criteria | NA (3.55 to NA) | NA (25.76 to NA) |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Serious adverse events (AEs) and other AEs: From Cycle 1 Day 1 up to 30 days post last dose of study drug (up to 38.3 months); all-cause mortality: from Cycle 1 Day 1 up to 3 years and 3 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Plus Androgen-deprivation Therapy (ADT) | 1/25 (4%) | 4/25 (16%) | 11/25 (44%) |
| Apalutamide 240 mg Plus ADT | 4/50 (8%) | 20/50 (40%) | 47/50 (94%) |
| Placebo + ADT to Apalutamide + ADT | 0/22 (0%) | 5/22 (22.7%) | 21/22 (95.5%) |
| All Participants: Apalutamide 240 mg Plus ADT | 4/72 (5.6%) | 25/72 (34.7%) | 68/72 (94.4%) |
| Event | Placebo Plus Androgen-deprivation Therapy (ADT) | Apalutamide 240 mg Plus ADT | Placebo + ADT to Apalutamide + ADT | All Participants: Apalutamide 240 mg Plus ADT |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/25 | 5/50 | 0/22 | 5/72 |
| LeukopeniaBlood and lymphatic system disorders | 0/25 | 0/50 | 1/22 | 1/72 |
| Gastritis ErosiveGastrointestinal disorders | 0/25 | 0/50 | 1/22 | 1/72 |
| Covid-19Infections and infestations | 0/25 | 2/50 | 1/22 | 3/72 |
| SepsisInfections and infestations | 0/25 | 0/50 | 1/22 | 1/72 |
| Femur FractureInjury, poisoning and procedural complications | 0/25 | 0/50 | 1/22 | 1/72 |
| Dermatitis Exfoliative GeneralisedSkin and subcutaneous tissue disorders | 0/25 | 0/50 | 1/22 | 1/72 |
| Mixed DeafnessEar and labyrinth disorders | 1/25 | 0/50 | 0/22 | 0/72 |
| Gastrointestinal Stromal TumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/25 | 0/50 | 0/22 | 0/72 |
| Cerebral InfarctionNervous system disorders | 1/25 | 0/50 | 0/22 | 0/72 |
| Event | Placebo Plus Androgen-deprivation Therapy (ADT) | Apalutamide 240 mg Plus ADT | Placebo + ADT to Apalutamide + ADT | All Participants: Apalutamide 240 mg Plus ADT |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 3/25 | 15/50 | 5/22 | 20/72 |
| RashSkin and subcutaneous tissue disorders | 3/25 | 14/50 | 4/22 | 18/72 |
| Covid-19Infections and infestations | 0/25 | 6/50 | 5/22 | 11/72 |
| HypertensionVascular disorders | 2/25 | 11/50 | 3/22 | 14/72 |
| Weight DecreasedInvestigations | 0/25 | 10/50 | 2/22 | 12/72 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/25 | 10/50 | 3/22 | 13/72 |
| PyrexiaGeneral disorders | 1/25 | 0/50 | 4/22 | 4/72 |
| LeukopeniaBlood and lymphatic system disorders | 0/25 | 9/50 | 3/22 | 12/72 |
| Rib FractureInjury, poisoning and procedural complications | 1/25 | 5/50 | 2/22 | 7/72 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/25 | 5/50 | 0/22 | 5/72 |
| Age, Continuous(Years) | Placebo Plus Androgen-deprivation Therapy (ADT) | Apalutamide 240 mg Plus ADT | Total |
|---|---|---|---|
| Mean | 74.5 ± 7.82 | 75.1 ± 7.90 | 74.9 ± 7.83 |
| Sex: Female, Male(Participants) | Placebo Plus Androgen-deprivation Therapy (ADT) | Apalutamide 240 mg Plus ADT | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 25 | 50 | 75 |
| Race (NIH/OMB)(Participants) | Placebo Plus Androgen-deprivation Therapy (ADT) | Apalutamide 240 mg Plus ADT | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 25 | 50 | 75 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo Plus Androgen-deprivation Therapy (ADT) | Apalutamide 240 mg Plus ADT | Total |
|---|---|---|---|
| China | 25 | 50 | 75 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Dec 2019 to primary completion in Jun 2023, 41 months.
Results were first posted in Mar 2025, 1 year 9 months after primary completion.
Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 41 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apalutamide
Janssen Research & Development, LLC →